Twin Tree Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-18,000
Closed -$9.45M 1783
2025
Q2
$9.45M Buy
18,000
+13,900
+339% +$7.76M 0.02% 789
2025
Q1
$2.6M Sell
4,100
-8,500
-67% -$5.85M ﹤0.01% 1084
2024
Q4
$8.98M Sell
12,600
-1,800
-13% -$1.51M 0.02% 730
2024
Q3
$15.1M Buy
+14,400
New +$16M 0.03% 503
2024
Q1
Sell
-6,200
Closed -$5.45M 1557
2023
Q4
$5.45M Buy
+6,200
New +$5.11M 0.01% 849
2023
Q2
Sell
-3,400
Closed -$2.79M 1473
2023
Q1
$2.79M Buy
+3,400
New +$2.56M 0.01% 851
2022
Q1
Sell
-7,000
Closed -$4.42M 1848
2021
Q4
$4.42M Buy
+7,000
New +$4.3M 0.01% 881
2021
Q1
Sell
-10,000
Closed -$4.83M 1571
2020
Q4
$4.83M Buy
+10,000
New +$5.4M 0.02% 638
2018
Q2
Sell
-33,800
Closed -$11.6M 1320
2018
Q1
$11.6M Sell
33,800
-123,400
-78% -$42.9M 0.09% 180
2017
Q4
$59.1M Buy
157,200
+82,300
+110% +$33.3M 0.44% 37
2017
Q3
$33.5M Sell
74,900
-16,000
-18% -$7.61M 0.27% 71
2017
Q2
$44.6M Sell
90,900
-50,000
-35% -$21.9M 0.35% 54
2017
Q1
$54.6M Buy
140,900
+118,600
+532% +$44M 0.5% 39
2016
Q4
$8.19M Sell
22,300
-32,500
-59% -$12.4M 0.08% 290
2016
Q3
$22M Buy
54,800
+8,800
+19% +$3.53M 0.28% 63
2016
Q2
$16.1M Buy
46,000
+30,200
+191% +$11.6M 0.25% 76
2016
Q1
$5.7M Buy
15,800
+2,800
+22% +$1.15M 0.11% 198
2015
Q4
$7.06M Buy
13,000
+300
+2% +$163K 0.14% 146
2015
Q3
$5.91M Buy
12,700
+6,800
+115% +$3.65M 0.15% 109
2015
Q2
$3.01M Hold
5,900
0.07% 277
2015
Q1
$2.66M Buy
5,900
+4,800
+436% +$2.03M 0.07% 311
2014
Q4
$451K Sell
1,100
-10,900
-91% -$4.29M 0.01% 788
2014
Q3
$4.33M Sell
12,000
-4,100
-25% -$1.37M 0.12% 200
2014
Q2
$4.55M Buy
16,100
+1,400
+10% +$415K 0.1% 212
2014
Q1
$4.41M Buy
+14,700
New +$4.53M 0.09% 262

Other funds holding REGN

Twin Tree Management's REGN Position: Q3 2025 in Review

Twin Tree Management sold out of Regeneron Pharmaceuticals (REGN) in Q3 2025, closing a stake of 4,891 shares — an estimated $2.57M sold.

Twin Tree Management first reported a position in REGN in Q2 2013 and held it in 31 quarters. The position peaked at $28M in Q1 2023. 1,244 funds tracked by Wall St. Rank hold REGN as of Q3 2025.

  • Twin Tree Management reported no remaining Regeneron Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Twin Tree Management sold 4,891 Regeneron Pharmaceuticals shares in Q3 2025, an estimated $2.57M.
  • Twin Tree Management first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 31 quarters.
  • Twin Tree Management's Regeneron Pharmaceuticals position peaked at $28M in Q1 2023.
  • 1,244 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2025.

Based on Twin Tree Management's 13F filing for Q3 2025, filed 13 Nov 2025.